Echo IQ (EIQ) investor relations material

Executive summary

• Net loss after tax for the half-year ended 31 December 2025 was $8.66 million, compared to $6.22 million in the prior corresponding period.

• Major clinical validation study for EchoSolv HF completed with Mayo Clinic Platform, achieving high diagnostic accuracy and exceeding expectations.

• Formal FDA 510(k) submission for EchoSolv HF lodged, targeting US market entry.

• Reseller agreement signed with SARC MedIQ to expand US distribution; onboarding with Sclmage and MedAxiom progressing.

• No significant changes in state of affairs or post-balance sheet events affecting future operations.

Financial highlights

• Revenue for the half-year was $90,909, down from $101,409 year-over-year.

• Other income increased to $299,809 from $172,345, including a $116,085 net gain on contract termination.

• Operating expenses rose, with employee costs at $2.58 million (vs $1.42 million), and share-based payments at $2.88 million (vs $2.27 million).

• Basic and diluted loss per share was 1.34 cents, compared to 1.09 cents in the prior period.

• Cash and cash equivalents at 31 December 2025 were $11.21 million, up from $6.62 million at 30 June 2025.

Outlook and guidance

• FDA clearance for EchoSolv HF would enable US market entry, unlocking significant commercial opportunities.

• Ongoing engagement with the American Medical Association to secure reimbursement pathways for AI-based diagnostics.

• Health economic outcomes study with NEDA aims to demonstrate clinical and cost benefits, supporting broader adoption.